Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 7/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13530731 | 0.82 | AR (0.52) | CCR4MAPK14LMNASLC40A1KDM4E | |
| SCHEMBL13530726 | 0.81 | AR (0.53) | CCR4MAPK14LMNAKDM4EHSD17B10 | |
| SCHEMBL13529811 | 0.81 | PARP14 (0.45) | HSD17B10 | |
| SCHEMBL13530257 | 0.81 | AURKA (0.42) | LMNAKDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL13530380 | 0.81 | AURKA (0.48) | KDM4EALDH1A1 | |
| SCHEMBL13530734 | 0.80 | CYP1A2 (0.48) | CCR4LMNASLC40A1ALDH1A1 | |
| SCHEMBL13530711 | 0.80 | AR (0.51) | CCR4MAPK14LMNASLC40A1KDM4E | |
| SCHEMBL13530495 | 0.80 | AURKA (0.41) | LMNAKDM4EALDH1A1GAA | |
| SCHEMBL13530567 | 0.80 | L3MBTL1 (0.49) | LMNAKDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL13529420 | 0.79 | MEN1 (0.49) | LMNAKDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9204653-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9204653-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9204653-B2 | 5-fluoro pyrimidine derivatives | DOW AGROSCIENCES LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022538-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | CCR4 1164/4885MAPK14 2523/4885HTR6 1849/4885 |
| US-20140024616-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES | DPYD, DPM1, DDX5 | CCR4 1164/4885MAPK14 2523/4885HTR6 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.